Related Experiment Video
Updated: Apr 25, 2026

Histological Analyses of Acute Alcoholic Liver Injury in Zebrafish
Published on: May 25, 2017
Alcohol-induced defects in hepatic transcytosis may be explained by impaired dynein function
Jennifer L Groebner1, David J Fernandez, Dean J Tuma
1Department of Biology, The Catholic University of America, 620 Michigan Avenue, NE, Washington, DC, 20064, USA.
Abstract:
Alcoholic liver disease has been clinically well described, but the molecular mechanisms leading to hepatotoxicity have not been fully elucidated. Previously, we determined that microtubules are hyperacetylated and more stable in ethanol-treated WIF-B cells, VL-17A cells, liver slices, and in livers from ethanol-fed rats. From our recent studies, we believe that these modifications can explain alcohol-induced defects in microtubule motor-dependent protein trafficking including nuclear translocation of a subset of transcription factors. Since cytoplasmic dynein/dynactin is known to mediate both microtubule-dependent translocation and basolateral to apical/canalicular transcytosis, we predicted that transcytosis is impaired in ethanol-treated hepatic cells. We monitored transcytosis of three classes of newly synthesized canalicular proteins in polarized, hepatic WIF-B cells, an emerging model system for the study of liver disease. As predicted, canalicular delivery of all proteins tested was impaired in ethanol-treated cells. Unlike in control cells, transcytosing proteins were observed in discrete sub-canalicular puncta en route to the canalicular surface that aligned along acetylated microtubules. We further determined that the stalled transcytosing proteins colocalized with dynein/dynactin in treated cells. No changes in vesicle association were observed for either dynein or dynactin in ethanol-treated cells, but significantly enhanced dynein binding to microtubules was observed. From these results, we propose that enhanced dynein binding to microtubules in ethanol-treated cells leads to decreased motor processivity resulting in vesicle stalling and in impaired canalicular delivery. Our studies also importantly indicate that modulating cellular acetylation levels with clinically tolerated deacetylase agonists may be a novel therapeutic strategy for treating alcoholic liver disease.
Insights
Ethanol disrupts protein transport in liver cells by altering microtubule function, leading to impaired liver function. Modulating cellular acetylation may offer a new treatment for alcoholic liver disease.
Area of Science:
- Hepatology
- Cell Biology
- Molecular Mechanisms of Disease
Background:
- Alcoholic liver disease pathogenesis involves complex molecular mechanisms.
- Ethanol exposure causes microtubule hyperacetylation and increased stability in hepatic cells.
- This impacts protein trafficking, including nuclear translocation of transcription factors.
Purpose of the Study:
- To investigate the effect of ethanol on transcytosis of canalicular proteins in hepatic cells.
- To elucidate the role of microtubule motor proteins in ethanol-induced hepatotoxicity.
- To explore potential therapeutic strategies for alcoholic liver disease.
Main Methods:
- Utilized polarized hepatic WIF-B cells as a model system.
- Monitored transcytosis of newly synthesized canalicular proteins.
- Analyzed protein colocalization with dynein/dynactin and binding to microtubules using microscopy and biochemical assays.
Main Results:
- Canalicular delivery of proteins was impaired in ethanol-treated cells.
- Stalled proteins colocalized with dynein/dynactin along acetylated microtubules.
- Ethanol exposure enhanced dynein binding to microtubules, suggesting reduced motor processivity.
Conclusions:
- Ethanol-induced hyperacetylation impairs microtubule motor function, leading to protein trafficking defects and hepatotoxicity.
- Enhanced dynein binding to microtubules results in vesicle stalling and impaired canalicular delivery.
- Modulating cellular acetylation levels may represent a novel therapeutic approach for alcoholic liver disease.
More Related Videos
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Hepatic Encephalopathy
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Cirrhosis II: Pathophysiology
Microtubule Associated Motor Proteins

